Encompass Health’s second quarter reflected robust demand for inpatient rehabilitation, with the company delivering revenue growth above Wall Street expectations and a double-digit gain in non-GAAP earnings per share. Management attributed the strong results to ongoing investments in clinical workforce development and capacity additions, as well as continued momentum in treating higher-acuity patient categories like stroke and brain injury. CEO Mark Tarr highlighted that the company’s patient outcomes “continue to exceed industry averages,” and cited the expansion of professional growth programs for clinical staff as a key factor behind lower turnover and reduced premium labor costs.
Is now the time to buy EHC? Find out in our full research report (it’s free for active Edge members).
Encompass Health (EHC) Q2 CY2026 Highlights:
- Revenue: $1.60 billion vs analyst estimates of $1.57 billion (9.6% year-on-year growth, 1.8% beat)
- Adjusted EPS: $1.55 vs analyst estimates of $1.48 (4.7% beat)
- Adjusted EBITDA: $348 million vs analyst estimates of $338.1 million (21.8% margin, 2.9% beat)
- The company slightly lifted its revenue guidance for the full year to $6.45 billion at the midpoint from $6.42 billion
- Management raised its full-year Adjusted EPS guidance to $6.14 at the midpoint, a 2.2% increase
- EBITDA guidance for the full year is $1.38 billion at the midpoint, above analyst estimates of $1.37 billion
- Operating Margin: 18.4%, in line with the same quarter last year
- Same-Store Sales rose 2.8% year on year (4.7% in the same quarter last year)
- Market Capitalization: $12.37 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Encompass Health’s Q2 Earnings Call
- Pito Chickering (Deutsche Bank) asked about how the company achieved leverage to raise EBITDA guidance despite lower Medicare pricing and higher wage growth assumptions; CFO Douglas Coltharp cited favorable pricing from higher patient acuity and benefits from staff retention initiatives.
- Matthew Gillmor (KeyBanc) followed up on North Carolina market opportunities; Coltharp said North Carolina could drive facility expansion toward the high end of the company’s annual target, with both large and small market potential.
- Ann Hynes (Mizuho Securities) questioned capital allocation between share repurchases and development; Coltharp emphasized that strong free cash flow enables both increased capital expenditures for growth and expanded shareholder returns.
- Benjamin Mayo (Leerink Partners) inquired about labor retention metrics; COO Patrick Tuer reported nursing turnover at a multi-year low and highlighted that career ladder participants have significantly better retention than non-participants.
- Andrew Mok (Barclays) asked if the gains in high-acuity admissions and same-store discharge growth are sustainable; Coltharp noted positive trends but cautioned that patient mix can fluctuate and the company avoids “cherry-picking” certain cases.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) the pace and success of new hospital and bed expansions, particularly in newly deregulated states like North Carolina; (2) ongoing execution of workforce development and retention programs, including their impact on premium labor costs; and (3) the company’s ability to scale pilot initiatives addressing payer denials and leverage AI-driven operational improvements. Trends in high-acuity patient admissions and regulatory developments will also remain key signposts.
Encompass Health currently trades at $125.33, up from $110.90 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
